News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Great Lakes Pharmaceuticals, Inc. Chooses OmniComm Systems, Inc. (OMCM)'s TrialMaster(R) Suite for Multi-National Pivotal Device Trial


4/10/2012 8:53:56 AM

FORT LAUDERDALE, FL--(Marketwire - April 10, 2012) - OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced that its TrialMaster® Suite of applications was chosen by Great Lakes Pharmaceuticals, Inc. (GLPI) to support their clinical research needs for a 20-month, multi-national pivotal device study involving up to 400 subjects across 20 sites.

Great Lakes Pharmaceuticals, Inc. is a clinical stage company focused on the development and commercialization of products designed to prevent infections associated with indwelling catheters. "Great Lakes Pharmaceuticals chose TrialMaster because it is a very straight-forward, configurable system with robust reporting capabilities," said Krzysztof Applet, Chief Executive Officer. "Our exceptional OmniComm team has exceeded expectations for both quality and timing of deliverables."

OmniComm will build and host the study for Great Lakes Pharmaceuticals, Inc., deploying TrialMaster® for EDC. OmniComm will train more than 60 site users for this study using their proprietary eLearning system and will work with Great Lakes Pharmaceuticals, Inc. and several clinical research organizations to manage this complex clinical trial by leveraging the latest in cutting-edge EDC technology.

"We are pleased to have been chosen by this prestigious organization," said Stephen Johnson, President and Chief Operating Officer of OmniComm. "This will be our first study together and we look forward to the challenge as we strive to deliver life-changing drugs/devices to market."

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life-changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small to large to maximize their clinical research investments. OmniComm Systems, Inc. has US headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the US and Europe.

About Great Lakes Pharmaceuticals, Inc.

Great Lakes Pharmaceuticals, Inc., (www.glpharma.com) is a research and development company focused on products designed to eliminate microbial infections associated with biofilm formation. The company plans to initiate a pivotal clinical trial for B-Lock™, its anti-biofilm catheter lock solution, in June 2012.

Safe Harbor Disclaimer

Statements made by OmniComm Systems, Inc. included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.



Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES